Corporate Member Roster
Meet our 2023 Prestigious Corporate Members.
Corporate Member Roster
Abarca Health LLC
We are a different kind of PBM and a different kind of company. Our entire organization has a culture of accountability, a sense of urgency, and an unstoppable commitment to finding a better way. Abarca has deep experience serving public and private sector organizations, including: Medicare and Commercial Health Plans, Self Insured Employers, State Medicaid Programs, and Large Insurers and PBMs. Americans are spending nearly half a trillion dollars every year on prescription benefits. It’s a system that isn’t working for payers, members, or providers. It doesn’t need to be this way. We believe costs should be lower, hassles should be fewer, and the experience should be better. And with a smarter technology and a straightforward approach to business, we are ready to lead the way.
Abbott Diabetes Care
Through a steadfast commitment to research, technology and state-of-the-art manufacturing, Abbott has developed a diverse portfolio of breakthrough diabetes products designed to meet the needs of each unique patient. Our innovative product development program is responsible for several groundbreaking technologies. Keep looking to our dedicated teams for the next generation of highly innovative and effective glucose monitoring products. We aim to set the standard for helping patients and healthcare providers to potentially achieve the best health outcomes.
AbbVie
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries.
ACADIA Pharmaceuticals, Inc.
At ACADIA (NASDAQ: ACAD), we share a passion for improving the lives of patients with central nervous system (CNS) disorders. Our vision is to become the leading pharmaceutical company dedicated to the advancement of innovative medicines that improve the lives of patients with CNS disorders. Our history is rooted in science and strong leadership in CNS research. We have set ourselves apart by transforming our novel discoveries into important drug candidates that may make a meaningful impact on the lives of patients and the family members who care for them every day.
Acorda Therapeutics, Inc.
Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. The Company currently has two FDA-approved therapies. INBRIJA® is approved for the intermittent treatment of OFF episodes in people with Parkinson’s disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda’s innovative ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also developed and markets AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, indicated to improve walking in people with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.
ADC Therapeutics
ADC Therapeutics is a clinical-stage oncology biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology. ADC Therapeutics has a deep understanding of antibody drug conjugate technology and the oncology treatment landscape. The company is dedicated to efficiently progressing its potential best-in-class PBD-armed ADCs to address significant unmet medical needs and improve outcomes for those with difficult-to-treat cancers. Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London (R&D), New Jersey (Clinical and Commercial) and the San Francisco Bay Area (CMC).
Akili Interactive Labs, Inc
Akili is pioneering the development of game-changing technologies to usher in a new era of cognitive medicine. Focused on delivering cutting-edge digital diagnostics, treatments and monitors for cognitive impairments across disease and disorders, Akili is combining scientific and clinical rigor with the ingenuity of the tech and entertainment industries and challenging the status quo of medicine. Akili’s treatments are designed to directly activate the networks in the brain responsible for cognitive function and have been rigorously tested in extensive clinical studies, including prospective randomized, controlled trials. Driven by Akili’s belief that effective medicine can also be fun and engaging, Akili’s products are delivered through captivating action video game experiences.
Albireo Pharma
Albireo is on a mission to create a better future for people living with rare pediatric and adult liver diseases. In addition to our scientific innovations, we are a company grounded in the principles of transformative medicines. Patients are the driving force behind everything that we do. We are committed to our employees and patients as well as the communities that we live and work in.
Alexion Pharmaceuticals
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent.
ALK Inc
As a world leader in allergy immunotherapy, ALK works to improve quality of life for the many allergy sufferers whose disease remains uncontrolled despite the use of symptom-relieving medication, by developing products that provide long-lasting relief. The company has approximately 2,000 employees, with subsidiaries, production facilities and distributors worldwide. ALK is headquartered in Denmark and listed on NASDAQ Copenhagen (OMX: ALK B).
Alkermes, Inc.
Alkermes is a fully integrated biopharmaceutical company that applies its scientific expertise and technological know-how to develop innovative medicines designed to yield better therapeutic outcomes for patients with central nervous system (CNS) disorders, including addiction, schizophrenia and depression.
Alnylam Pharmaceuticals
Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases with high unmet medical need. Alnylam was founded in 2002 on a bold vision to turn scientific possibility into reality, which is now marked by its robust discovery platform and deep pipeline of investigational medicines, including 4 programs in late-stage clinical development.
Amarin Pharma, Inc.
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin's clinical program includes commitment to providing grants to support research and education in the disease state including the funding of an ongoing outcomes trial. Vascepa® (icosapent ethyl), Amarin’s first FDA approved product, is a highly-pure, EPA-only, omega-3 fatty acid product availably by prescription.
Amgen, Inc.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, with a presence in approximately 100 countries and regions worldwide. Our innovative medicines have reached millions of people in the fight against serious illnesses, with a focus on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation. Our medicines typically address diseases for which there are limited treatment options, or they are medicines that provide a viable option to what is otherwise available.
Apellis
We are a global biopharmaceutical company leveraging courageous science, creativity, and compassion to deliver life-changing therapies. By pioneering targeted C3 therapies, we aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology.
Ascendis Pharma
Ascendis Pharma is applying its innovative TransConTM technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’ lives.
Guided by our core values of patients, science and passion, we utilize our technology platform to create new and potentially best-in-class therapies. We currently have a pipeline of three independent, rare disease endocrinology product candidates in clinical development. We have also established oncology as our second therapeutic area of focus.
Astellas Pharma US, Inc.
Launched in April 2005, Astellas was formed by the historical merger of Japan’s third and fifth largest pharmaceutical companies- Yamanouchi, founded in 1923, and Fujisawa, founded in 1894. Created from a partnership of two respected, leading global companies, Astellas is built on a strategic platform focused in select therapeutic areas: Cardiology, Dermatology, Immunology, Infectious Disease, Oncology and Urology. Within each therapeutic area, Astellas focuses on unsurpassed science and building networks of trust among physicians, patients and partners. Key strategic products include: Prograf, VESIcare, Lexiscan, Adenoscan, Protopic, Amevive, AmBisome and Mycamine.
AstraZeneca, L.P.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Avadel
Avadel Pharmaceuticals plc is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, FT218, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
Avalere Health, LLC
Avalere Health is a strategic advisory company whose core purpose is to create innovative solutions to complex healthcare problems. Based in Washington, D.C., the firm delivers actionable insights, business intelligence tools and custom analytics for leaders in healthcare business and policy. Avalere's experts span 230 staff drawn from Fortune 500 healthcare companies, the federal government (e.g., CMS, OMB, CBO and the Congress), top consultancies and nonprofits. The firm offers deep substance on the full range of healthcare business issues affecting the Fortune 500 healthcare companies. Avalere's focus on strategy is supported by a rigorous, in-house analytic research group that uses public and private data to generate quantitative insight. Through events, publications and interactive programs, Avalere insights are accessible to a broad range of customers.
Aventine Consulting, LLC
Aventine is a consulting firm specializing in the development of formulary submission dossiers and economic modeling and comprised of a strategic team of highly experienced managed care clinicians who understand the needs of the payer audience. Our team leverages our past professional experience on the payer side of the access equation to create dossiers and models that are fit for purpose. We develop scientifically-sound, evidence-based, high-quality deliverables supporting the true value of our clients’ products and have decades of experience communicating to the US payer audience. Our team prides itself on the integrity of our work, the trusted relationships we have forged with our clients, and our outstanding customer return and retention. Since Aventine’s inception in 2008, our strong reputation as a personable and accountable boutique consulting firm has become one of our greatest professional assets. Ask around – our active client base includes companies of all sizes: from the smallest start-ups to the largest pharma companies.
Bausch & Lomb, Inc.
Bausch & Lomb, Inc. is the preeminent global technology-based healthcare company for the eye, dedicated to helping consumers see, look and feel better through innovative technology and design. Its core businesses include soft and rigid gas permeable contact lenses, lens-care products, ophthalmic surgical and pharmaceutical products. Today, Bausch & Lomb is the only company with product offerings for every major aspect of refractive surgery. The company’s new technologies provide even more options to help surgeons meet a wider variety of patients’ vision correction.
Bayer
Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With our innovative products, we are contributing to finding solutions to some of the major challenges of our time.
At Pharmaceuticals, our largest segment in terms of sales, we focus on researching, developing and marketing specialty-focused innovative medicines that provide significant clinical benefit and value, primarily in the therapeutic areas of cardiology, oncology, gynecology, hematology and ophthalmology. In this way, we are addressing the growing requirements of patients, physicians, health care payers and regulatory agencies.
Science for a Better Life
BeiGene USA, Inc.
Our mission is to become a global leader in the discovery, development, and commercialization of innovative, molecularly-targeted, and immuno-oncology drugs for the treatment of cancer. At BeiGene, we are passionate about our people, science, and creating a lasting impact. These priorities are of utmost importance to our organization. We strive to build a global organization recognized for its impact in cancer research and drug development, talented people, and integrity. As part of our global clinical development program, we’re enrolling patients in 34 countries to participate in our clinical trials. We’re a dynamic company, with a bold vision and bright future. We’re looking for highly motivated colleagues who can collaborate with us, as we build a company that will have a lasting impact in the global fight against cancer.
Biogen
Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies.
Boehringer Ingelheim Pharmaceuticals, Inc.
Improving the health and quality of life of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of 17.5 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 18.1 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
Bristol-Myers Squibb Company
At Bristol Myers Squibb, we believe in the power of science to address some of the most challenging diseases of our time. Our focus on these unmet needs comes during a remarkable time, when unprecedented scientific breakthroughs are advancing the treatment of disease as never before in human history. We are proud of the advancements we have made in oncology, hematology, immunology and cardiovascular disease, and we are dedicated to helping patients prevail over serious diseases through our diverse and promising pipeline and new scientific platforms.
Calliditas NA Enterprise Inc
Calliditas Therapeutics is a specialty pharmaceutical company headquartered in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the Company can partially or completely participate in the commercialization efforts. The Company is focused on the development and commercialization of the product candidate Nefecon, a two-step unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas Therapeutics is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the US.
Certara
The drug discovery and development process is complex and risk-laden with more failures than successes. As your trusted partner, we accelerate medicines to patients, using biosimulation and technology-enabled services to transform drug discovery and development. Our integrated and proprietary end-to-end platform with biosimulation, regulatory science, and market access solutions combined with our 900+ strong team of scientists and experts enable informed decision-making, higher R&D productivity, and improved patient outcomes.
ChemoCentryx
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives.
Chiesi USA
Chiesi USA is a specialty pharmaceutical company committed to research, development, production and commercialization of innovative products in the areas of cardiovascular, respiratory, neonatology, rare disease and special care therapeutics. Our primary focus is on people: the people we serve in the healthcare community; the people whose lives are touched by our products and services; and the people who work at Chiesi USA, as they strive to build their company, their family and their community.
Coherus Biosciences
Coherus BioSciences is focused on expanding patient access to important, cost-effective medicines and delivering significant savings to the U.S. healthcare system. Every member of the Coherus team is dedicated, motivated, and passionate about expanding patient access to lifesaving therapeutics. Coherus was founded in 2010 to provide the highest quality biosimilar treatments to patients. We are proud to now be expanding our legacy—to build on our success with biosimilars and to focus our core strengths on immuno-oncology.
CSL Behring
CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. We use three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and continually refine ways in which products can address unmet medical needs and help patients lead full lives. CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. The parent company, CSL Limited headquartered in Melbourne, Australia, employs more than 25,000 people worldwide, and delivers its life-saving therapies to people in more than 100 countries.
CVS Health
CVS is headquartered in Woonsocket, RI, the largest pharmacy health care provider in the U.S. and has integrated offerings across the spectrum of pharmacy care that involves more than 246,000 colleagues across all 50 states, Washington, D.C., Puerto Rico and Brazil. Millions of times a day, we’re helping people on their path to better health—from advising on prescriptions to helping manage chronic and specialty conditions. Because we’re present in so many moments, big and small, we have an active, supportive role in shaping the future of health care
Cytokinetics
We are developing potential medicines to improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function, like heart failure, hypertrophic cardiomyopathies (HCM), amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). By focusing on impacting the mechanics of muscle with investigational medicines that may improve strength, power, or performance, we aspire to develop new treatment options that may dramatically improve the lives and functionality of people living with debilitating diseases.We have conducted more than 50 clinical trials as we strive to bring important new medicines to patients with diseases like ALS, heart failure, HCM and SMA.
Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is the U.S. subsidiary of Japan-based Daiichi Sankyo Co., Ltd., one of the twenty largest pharmaceutical companies in the world and a global leader in pharmaceutical innovation since 1899. The company is dedicated to the discovery, development and commercialization of innovative medicines that improve the lives of patients throughout the world.
The primary focus of Daiichi Sankyo’s research and development is Oncology The company is also pursuing the discovery of new medicines in the areas of glucose metabolic disorders, infectious diseases, cancer, bone and joint diseases, and immune disorders.
Dermavant Sciences, Inc.
Dermavant Sciences, a subsidiary of Roivant Sciences, is a clinical-stage biopharmaceutical company committed to fostering unprecedented change and unparalleled impact in immuno-dermatology. We’re doing this by thinking differently, pushing the boundaries of science and partnering with providers in new ways—all with one goal: transforming the lives of millions of patients with skin diseases.
Dexcom Inc.
Founded in 1999, Dexcom, Inc. is transforming diabetes care and management by providing superior continuous glucose monitoring (CGM) technology to help patients and healthcare professionals better manage diabetes. Since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions that are best in class—while empowering our community to take control of diabetes
Eisai, Inc.
Satisfying diverse healthcare needs around the world ~ Around the world there are still many diseases for which no effective treatments exist and many patients who do not have adequate access to the medicines they need. As a global pharmaceutical company addressing these unmet medical needs, Eisai is committed to making contributions to better healthcare for patients and their families around the world through its business activities.
embecta
embecta, formerly part of BD (Becton, Dickinson and Company), is one of the largest pure-play diabetes care companies in the world, leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com.
EMD Serono Inc.
EMD Serono, Inc. is committed to discovering and developing medicines that address unmet medical needs. EMD Serono focuses its business in the areas of neurology, reproductive health, metabolic endocrinology, oncology, and autoimmune disease, integrating innovative science with comprehensive patient support systems to improve lives. Visit us at www.emdserono.com.
Emerging Therapy Solutions
Emerging Therapy Solutions® (ETS) helps healthcare payers – including reinsurance and stop-loss payers, health plans and self-funded employers – manage the risks associated with high-cost therapies for rare and complex conditions. We offer a comprehensive suite of services for solid organ and bone marrow transplants, cell and gene therapies, and other highly specialized therapies.
EnlivenHealth
EnlivenHealth™ provides the most proven and advanced technology solutions for intelligent patient engagement and communications. Trusted by a national network of leading pharmacies, the EnlivenHealth™ Patient Engagement Platform empowers pharmacies and health plans to significantly improve medication management, adherence and safety for their patient populations. Our mission is to help you ensure lifelong optimal health for your patients and members, measurably improve quality scores, and strengthen business results. EnlivenHealth™ is a division of Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies.
EVERSANA
We set our sight on a simple, but powerful vision to advance life science services toward a healthier world. The journey began when Water Street Healthcare Partners and JLL Partners joined forces to acquire and combine the most comprehensive platform of life sciences services in the industry. Together, we are EVERSANA. We offer more than 500 clients – from start-ups to established global pharmaceutical leaders – the services they need to bring critical therapies to market while improving the lives of patients around the world.
Exelixis, Inc.
Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead compounds, cabozantinib and cobimetinib, tells the story of our evolution as a company. Each of these compounds were discovered in our own laboratories and advanced by us into clinical development. Exelixis was founded and incorporated in 1994 and we are based in South San Francisco, California. Exelixis is dedicated to improving the care of, and outcomes for patients with cancer.
Ferring Pharmaceuticals Inc.
As a privately-owned, biopharma company, Ferring focuses on developing life-changing innovations that help people live better lives. Grounded in a 70-year commitment to science and research, we are relentless in our pursuit of therapies that help people build families, stay healthy, and fight disease. We’re committed to being the world-leading, most trusted healthcare company in reproductive medicine and maternal health, and a leader in specialty areas within gastroenterology and orthopaedics. With that ambition in mind, we’re dedicated to following the science, conducting exhaustive research, and going where others may not—which means that people will always come first.
Fresenius-Kabi
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Our products and services are used to help care for critically and chronically ill patients.
G1 Therapeutics
G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is currently advancing three clinical-stage oncology programs. Two of our product candidates, trilaciclib and lerociclib, have broad therapeutic potential and may serve as backbone therapies for multiple combination regimens. Our third product candidate, G1T48, is a potential best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of estrogen receptor-positive (ER+) breast cancer. All three investigational therapies have the potential to become new standards of care for women living with breast cancer and provide benefit at early stages of their disease, including in the adjuvant setting. G1 owns or holds an exclusive license for worldwide commercial rights to each of its product candidates.
Genentech Inc.
Genentech, Inc. is a leading biotechnology company focusing on the discovery, development, manufacture, and marketing of pharmaceuticals for significant, unmet medical needs. Genentech’s managed care specialists are committed to enhancing the quality and delivery of patient care by working with managed care organizations to find effective solutions to health care issues.
Genmab
Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. For more than 20 years, Genmab’s vision to transform cancer treatment has driven its passionate, innovative and collaborative teams to invent next-generation antibody technology platforms and leverage translational research and data sciences, fueling multiple differentiated cancer treatments that make an impact on people’s lives. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab’s proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.
Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
Grail
Survival rates are higher when cancer is diagnosed at earlier stages. However, effective screening only exists for a few cancer types, and most cancer is detected at later stages, when survival rates are much lower. We believe we are taking on one of the biggest challenges of our lifetime, combining science, technology, and population-scale clinical studies to reveal cancer at its beginnings. To detect cancer early, when it can be cured. At GRAIL, we find purpose in our mission and call on our passion as we tackle one of the most important problems in the world.
GSK
GlaxoSmithKline (GSK), one of the world’s leading research-based health care companies, discovers, develops, manufactures and markets pharmaceuticals, vaccines, over-the-counter medications and health-related products. GSK’s people are committed to fighting disease by bringing innovative medicines and services to patients throughout the world and to the health care providers who serve them.
Horizon Therapeutics
At Horizon, we define our success by a different set of numbers: the number of lives touched, the number of lives changed, the number of lives saved. As we build a growing pipeline and explore all potential uses for our medicines, we strive to make a powerful difference for our patients, their caregivers and physicians every day. Our drive to deliver breakthrough therapies comes from our deep understanding of the patient journey. These patients’ courage inspires us – and drives us to listen, collaborate and build communities. That’s why, at our core, we believe science and compassion must work together to transform lives.
HUTCHMED
HUTCHMED is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 4,500 personnel across all its companies, at the center of which is a team of over 1,400 in oncology/immunology. Since inception it has advanced eleven cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed in China.
Illumina, Inc.
ImmunoGen
ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.
Incyte Corporation
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. The company’s first commercial product, Jakafi® (ruxolitinib), an oral JAK1 and JAK2 inhibitor, is approved by the FDA to treat two rare blood disorders--first approved in November 2011 Jakafi received a subsequent U.S. approval in December 2014.
Inovalon
Inovalon is a leading provider of cloud-based platforms empowering data-driven healthcare. Through the Inovalon ONE® Platform, Inovalon brings to the marketplace a national-scale capability to interconnect with the healthcare ecosystem, aggregate and analyze data in real time, and empower the application of resulting insights to drive meaningful impact at the point of care. Leveraging its Platform, unparalleled proprietary datasets, and industry-leading subject matter expertise, Inovalon enables better care, efficiency, and financial performance across the healthcare ecosystem. From health plans and provider organizations, to pharmaceutical, medical device, and diagnostics companies, Inovalon’s unique achievement of value is delivered through the effective progression of “Turning Data into Insight, and Insight into Action®.” Supporting thousands of customers, including all 25 of the top 25 U.S. health plans, all 25 of the top 25 global pharma companies, 24 of the top 25 U.S. healthcare provider systems, and many of the leading pharmacy organizations, device manufacturers, and other healthcare industry constituents, Inovalon’s technology platforms and analytics are informed by data pertaining to more than one million physicians, 584,000 clinical facilities, 338 million Americans, and 63 billion medical events.
Insulet Corporation
Insulet Corporation, headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.
Ionis Pharmaceuticals
Ionis is THE leading innovator in RNA-targeted therapeutics and was purposely designed to 1) Create a better, more efficient drug discovery platform, 2) Establish a new innovation-centered business model, and 3) Maximize the value of every medicine we create and get it to the people who need it most as quickly and as efficiently as possible. Today we are a sustainably profitable, multi-product company that is delivering transformative breakthroughs for patients… again and again.
Ipsen Biopharmaceuticals
Ipsen is a leading biopharmaceutical group dedicated to improving lives through innovative medicines in oncology , neuroscience and rare diseases. Ipsen’s mission, “innovation for patient care”, highlights the Group’s determination to focus on patients and unmet medical needs and to provide innovative therapeutic solutions. As well as our dedication to improving the lives of patients, Ipsen is also firmly committed to protecting the environment and to supporting civil society and the communities in which we operate. The Group is pledged to promote ethical, responsible and transparent professional practices.
Iveric Bio
We see a world where vision is preserved. Pioneering transformational therapies for people with retinal diseases.
Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases — often with limited or no options — so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again.
Johnson & Johnson Health Care Companies
Johnson & Johnson Health Care Companies are committed to creating measurable value for our managed markets customer through a dedicated focus on meeting your needs. In doing so, we will draw on our wide range of innovative products and services. We can work together to improve your clinical and business outcomes.
Kadmon Pharmaceuticals
Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Our team has a proven track record of successful drug development and commercialization. Our clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.
Kaleo
Kaléo is a fully integrated pharmaceutical company dedicated to inventing, manufacturing and commercializing life-transforming products that empower patients with certain serious and life-threatening medical conditions to live fuller, bolder lives. We believe patients and caregivers are the experts on how medical conditions impact their lives, and so we include them as an integral part of our development process and consider their needs foremost. Kaléo’s innovative auto-injection technologies are protected by an extensive intellectual property portfolio of more than 200 issued patents. Kaléo is headquartered in Richmond, Virginia in the United States. For more information, visit www.kaleo.com.
Karuna Therapeutics
Kiniksa Pharmaceuticals
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation.
Kroger Prescription Plans
Kroger Prescription Plans has provided comprehensive Pharmacy Benefits Management services since 1993. We combine transparency and highly competitive pricing to drive lower costs for clients and their members, while at the same time delivering exceptional customer service. Our plans are flexible and adaptable. Kroger Prescription Plans is focused on improving the health & wellness of our customers. We are committed to advancing health, reducing costs and improving the efficacy of any client’s health strategy.
LEO Pharma
LEO Pharma Inc. is the U.S. affiliate of Denmark-based LEO Pharma A/S, a global leader in dermatology. LEO Pharma products have been available in the U.S. since 1994, and the company opened the U.S. affiliate in January 2010. The company's U.S. offices are located in Madison, N.J. LEO Pharma has a 100+ year history as a specialty pharmaceutical company, committed to the discovery and development of novel drugs for patients; markets products in 100+ countries worldwide; employs 6,000 dedicated colleagues operating across 61 countries, and remains wholly owned by The LEO Foundation and is headquartered in Ballerup, Denmark, outside Copenhagen.
Lilly USA, LLC
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquarted in Indianapolis, IN, Lilly provides answers – through medicines and information – for some of the world’s most urgent medical needs.
Luminopia
Luminopia is pioneering a new class of treatments for significant neurovisual disorders. We have proven in randomized, controlled trials that presenting visual stimuli within a VR headset, while engaging patients with popular TV shows and movies, can significantly improve vision in pediatric amblyopia. We are now expanding this science and know-how to other neurovisual diseases such as strabismus, stroke and traumatic brain injury.
Magellan Rx Management
At Magellan Rx Management, we are a full-service pharmacy benefits manager (PBM) that specializes in solving complex pharmacy challenges for our customers. We believe in developing and executing smart solutions that leverage our industry-leading experience and technology to exceed expectations across the following lines of business: Employer, Third Party Administrator, Broker; Managed Care; Government, Medicaid, Medicare Part D. As a pioneer in medical specialty pharmacy management and a leader in best-in-class formulary optimization programs, we deliver consistent, proven cost savings. As clinical experts, we deliver customized programs to address our clients’ most pressing clinical challenges, drive STAR improvements, and engage patients and providers to deliver improved health outcomes. elcome to a unique vision of care. Magellan Rx Management is a division of Magellan Health, Inc.
Mallinckrodt
Mallinckrodt is a global specialty pharmaceutical company. Focus areas include therapeutic drugs for autoimmune and rare-disease specialty areas along with analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. Mallinckrodt’s Specialty Pharmaceuticals segment includes branded and specialty generic drugs and active pharmaceutical ingredients.
Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
MedImpact Healthcare Systems, Inc.
MedImpact is the PBM that puts clients and consumers first. For 30 years, it has had a single mission: To make pharmacy benefits affordable, understandable, and transparent. Today, MedImpact’s team and technology serve many large employers and plans, and more than 55 million consumers in the US and around the world. Learn more at medimpact.com or follow us on Twitter @MedImpact.
Mercer Government
Mercer believes in building brighter futures by redefining the world of work, reshaping retirement and investment outcomes, and unlocking real health and well-being. Mercer’s approximately 25,000 employees are based in 43 countries and the firm operates in 130 countries. Mercer is a business of Marsh McLennan (NYSE: MMC), the world’s leading professional services firm in the areas of risk, strategy and people, with 83,000 colleagues and annual revenue of approximately $20 billion. Through its market-leading businesses including Marsh, Guy Carpenter and Oliver Wyman, Marsh McLennan helps clients navigate an increasingly dynamic and complex environment.
Merck & Co., Inc.
Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work wtih customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.
MHK
MHK helps health plans and pharmacy benefit managers deliver optimal care across every member's health journey through innovative technology that provides critical insights from enrollment and through every stage of care.
MHK’s CareProminence Pharmacy Management Suite is where care and knowledge converge, bringing together all pharmacy management activities, including integration with ePA vendors, to ensure compliance timeliness, reduce administrative costs, and improve drug safety. With a comprehensive view of every member through the platform’s 360Member profile, customers are better equipped to make well-informed clinical decisions in support of optimal health outcomes.
Milliman
Independent for over 70 years, Milliman delivers market-leading services and solutions to clients worldwide. With no agenda, other than getting it right.Through a team of professionals ranging from actuaries to clinicians, technology specialists to plan administrators, we offer unparalleled expertise in employee benefits, investment consulting, healthcare, life insurance and financial services, and property and casualty insurance.
Moderna Inc.
In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.
Nektar Therapeutics
Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer and auto-immune disease. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new drug candidates.
Neurelis
Neurelis is a unique company focused on therapies for disorders involving the central nervous system. Our company is built on a foundation of passion and progress. This passion fuels our drive to successfully deliver innovative therapies that have the potential to change the lives of patients, caregivers, and healthcare providers. Neurelis is a neuroscience-based specialty pharmaceutical company dedicated to enhancing therapeutic benefit and addressing unmet needs in patient care.
Novartis Gene Therapies
Since 2013, Novartis Gene Therapies (formerly AveXis) has had one focus: bringing change to those devastated by genetic diseases. The Novartis Gene Therapies culture embraces this mission. As a compassionate and dedicated team, we are enthusiastic about the science behind our work, breaking barriers, and finding answers to difficult questions. We are dedicated to communities affected by rare diseases, and these patients and families are the motivation for everything we do.
Novartis Pharmaceuticals (Medical)
Our purpose is to reimagine medicine to improve and extend people's lives. We use innovative science and technology to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our company.
Strategy: Our strategy is to build a leading, focused medicines company powered by advanced therapy platforms and data science.
Pipeline: Benefitting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines with more than 150 projects in clinical development.
Novartis Pharmaceuticals Corporation
Novartis Pharmaceuticals Corporation is committed to improving health and quality of life by focusing on the discovery, development, manufacture and marketing of innovative, effective and safe prescription medications. Key therapeutic areas include Cardiovascular, Endocrine & Respiratory Diseases, Gastroenterology; Central Nervous System Disorders; Dermatology; Oncology/Hematology; Rheumatism/Bone & Hormone Replacement Therapy and Transplantation. Located in East Hanover, NJ, Novartis Pharmaceuticals is an affiliate of Novartis AG, a world leader in Healthcare in more than 140 countries with core businesses in pharmaceuticals, consumer health, generics, eyecare, and animal health.
Novo Nordisk, Inc.
Novo Nordisk Inc. is a focused healthcare company. With a broad diabetes product portfolio, including innovative products within the area of insulin delivery systems, Novo Nordisk is a world leader in diabetes care. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession, and society. Worldwide, Novo Nordisk employs an estimated 18,800 people in 69 countries and markets its products in 179 countries. Novo Nordisk's global headquarters is located in Denmark where the company began more than 80 years ago with the North American affiliate headquartered in Princeton, NJ.
Optinose, Inc.
The Optinose team is unified by a common shared mission: to improve lives. We will accomplish this while creating value for investors and the healthcare system along with better outcomes for patients and providers. As innovators in every aspect of our work, we will pursue faster and less costly product development, explore evolving commercial business models, and actively seek innovative ways to be more effective and efficient. We are committed to working together as a team that chooses to live every day by core company values that guide our daily behaviors, creating a foundation for future success.
Organon USA Inc.
Organon Pharmaceuticals USA Inc. is the U.S. affiliate of N.V. Organon, a renowned international ethical pharmaceutical company. Organon – with shared head offices in Roseland, N.J., USA and Oss, The Netherlands – creates, manufactures and markets prescription medicines that improve the health and quality of human life. Through a combination of independent growth and business partnerships, Organon strives to remain or become one of the leading pharmaceutical companies in each of its cores therapeutic fields: reproductive medicine, psychiatry and anaesthesia. Organon products are sold in over 100 countries, of which more than 60 have an Organon subsidiary. Organon is the human health care business unit of Akzo Nobel. Akzo Nobel is an international company active in the areas of pharmaceuticals, coatings and chemicals with approximately 61,000 employees and operations in over 80 countries.
Otsuka America Pharmaceutical, Inc.
Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: “Otsuka–people creating new products for better health worldwide.” Otsuka researches, develops, manufactures and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health. In pharmaceuticals, Otsuka is a leader in the challenging areas of mental, renal and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does. Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI).
Outcomes
Outcomes™ was formed to address the need in healthcare for a holistic patient engagement ecosystem that aligns pharmacies, payers and pharmaceutical manufacturers. The company was created in 1999 by unifying and building upon the proven, industry-leading programs and platforms of OutcomesMTM™, mscripts™ and TelePharm™. Outcomes combines patient engagement solutions and tools for the pharmacy of the future. Rooted in the pharmacist-patient relationship, Outcomes™ is designed to support close relationships across healthcare—all with the goal of improving patient outcomes.
Oyster Point Pharma, Inc.
Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases. In October 2021, Oyster Point Pharma received FDA approval for TYRVAYA™ (varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease. Oyster Point has a growing pipeline of clinical and pre-clinical programs and continues to expand its research and development pipeline through internal innovation and external collaborations. Oyster Point Pharma is continuously striving to advance breakthrough science and deliver therapies seeking to address the unmet needs of patients with ophthalmic disease and the eye care professionals who take care of them.
Pear Therapeutics
At Pear, our mission is clear: we are pioneers in PDTs. Our cross-functional team operates at the intersection of biology and software technology. Pear discovers, develops, and delivers clinically validated software to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Every day, we push the boundaries of technology to transform medicine.
Pearldiver Technologies
PerformRx
PerformRx? is an NCQA and URAC-accredited, next-generation pharmacy benefits manager located in Philadelphia, PA. Formed in 1999, PerformRx maintains a clinical culture, providing cost-effective therapies and extensive evidence-based programs at an optimal cost to its clients. PerformRx’s best-in-class pharmacy benefit management services include formulary development, drug therapy management and rebate management. PerformSpecialty® is PerformRx’s wholly-owned and integrated specialty pharmacy. Markets serviced by PerformRx include Medicaid, Medicare, commercial and employer group.
Pfizer Inc.
As one of the world’s leading healthcare companies, Pfizer has developed and brought to market medicines for humans and animals for over 150 years. Our portfolio includes more category-leading medicines than any other company – treatments that are helping countless people everyday to ease arthritis and nerve pain, manage depression, fight diabetes and cancer and control hypertension. Our portfolio of innovative medicines currently includes treatments for more than a dozen disease areas and we are targeting unmet medical needs through state-of-the-art research and development.
We know that healthcare is more than a business—it’s a mission-and our products can only help people if they can get them. That’s why we are deeply committed to enhancing access to high-quality healthcare. This year, through innovative partnership programs, Pfizer is giving product donations for patients in need around the world and building the infrastructure necessary to ensure that the medicines get to those who need it most.
The value of medicine. The benefits of research. The commitment to help meet the needs of those in need. At Pfizer, we dedicate ourselves to humanity’s quest for longer, healthier, happier lives through innovation in pharmaceutical, consumer and animal health products.
Pharmaceutical Strategies Group
We are your advocate in drug management. For over 25 years PSG has been singularly focused on helping our clients navigate the complex and ever-changing challenges of drug management. Through our leading pharmacy intelligence and technologies, we save our clients billions of dollars every year with an unwavering commitment to serving as your advocate and strategic partner. Our mission is to relentlessly advocate for our clients as we partner together to develop innovative drug management solutions that deliver exceptional insights, financial and clinical value.
Pharmacy Quality Solutions, Inc.
Pharmacy Quality Solutions (PQS), is the leading provider of performance management services representing nearly 80% of Medicare Advantage payers and 95% of community pharmacies. PQS delivers the quality insights and guidance necessary to support its customers’ efforts to optimize the quality of medication management and use for their Medicare, Medicaid and commercial populations. PQS connects medication use stakeholders to actionable, quality information in a consistent and reliable fashion, allowing them to move more quickly from measurement to improvement. Its industry-leading platform, EQuIPP™, provides dependable measurement and reporting on key medication use quality measures, including addressing medication adherence, gaps in care, and patient safety. PQS provides measurement insights that are timely, actionable, and simply understood.
Precision for Value & Health
Precision for Medicine, headquartered in Bethesda, MD, is a specialized company providing services and infrastructure to support life sciences companies as they develop new products in the age of precision medicine. Precision brings expertise, technology, and project execution to support innovative, patient-centric solutions from discovery through commercialization.
Precision for Value supports commercial excellence for global pharmaceutical and life sciences clients through the proficient demonstration of product value and outcomes. With locations in New York City, New Jersey, Chicago, Boston, Connecticut, and Indianapolis, Precision for Value’s teams provide clients with services grounded in decades of industry knowledge, demonstrated analytics proficiency, and marketing and communications prowess—making Precision for Value the preferred strategic partner in the industry.
Precision Advisors combines unrivaled real-world market experience with thought leadership and industry expertise to provide insight, strategy and advice to innovative life science companies. Headquartered in Cambridge, Massachusetts, Precision Advisors’ unmatched team of expert advisors encompass all areas of the commercialization spectrum including strategy consulting, managed markets, health economics, clinical research and analytics.
Premier, Inc.
PINC AI™ Applied Sciences (PAS) is a trusted leader in accelerating healthcare improvement through services, data, and scalable solutions, spanning the continuum of care and enabling sustainable innovation and rigorous research. These services and real-world data are valuable resources for the pharmaceutical, device and diagnostic industries, academia, federal and national healthcare agencies, as well as hospitals and health systems. Since 2000, PAS researchers have produced more than 825 publications which appear in 264 scholarly, peer-reviewed journals, covering a wide variety of topics, and conduct population-based analyses of drugs, devices, treatments, disease states, epidemiology, resource utilization, healthcare economics and clinical outcomes.
Prime Therapeutics LLC
Prime Therapeutics is an independent pharmacy benefit manager that is committed to the health of those we serve. Our "people over profits" approach reflects our privately held heritage. We also believe it produces the best results. Our health care system is fragmented. Instead of working together, doctors, pharmacists, and insurers often focus only on their own pieces of the puzzle. Poor communication and lack of coordination cause errors and create gaps in care. Prime has a different view. Because we are collectively owned by non-profit health plans, we never forget that drugs are part of a bigger picture. We exchange pertinent data and insights with health plans and work with them to coordinate across pharmacy and medical benefits. We leverage our unique connections to deliver programs that lead to the best health outcomes.
Provention Bio
The lives of patients and their families are the primary motivators at Provention Bio. Before they become patients for life, before their days are cut short, we look to intervene by researching, developing, and bringing medicines to market that have the potential to intercept and prevent autoimmune diseases that would have otherwise robbed them of their full lifetime of potential. We are aiming to bring novel medicine to practice through ingenious science and unrelenting partnerships so that together we can change the world.
Regeneron
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.
Replimune
Rx Savings Solutions
RxAnte
RxAnte is a leading predictive analytics and clinical services company located in Portland, Maine, and Washington, D.C., dedicated to improving medication use and health outcomes. By providing plans, providers, and manufacturers with actionable insights, strategies, and our own portfolio of interventions, RxAnte empowers clients with the resources necessary to help make medications work better for everyone.
RxBenefits
RxBenefits is a technology-enabled pharmacy benefits optimizer (PBO) with more than 750 pharmacy pricing, data, and clinical experts working together to deliver prescription benefit savings to employee benefit consultants and their self-insured clients. With more than 3 million members, RxBenefits brings market-leading purchasing power, independent clinical solutions, and high-touch service to its customers – ensuring that all plan sponsors, regardless of size, can provide an affordable and valuable pharmacy benefit plan to their employees. The company is headquartered in Birmingham, AL with a second office in Towson, Maryland.
RxParadigm
RxParadigm was founded by a team of seasoned Pharmacy Benefit Management Professionals to restore competitiveness and simplify the marketplace with ingenuity, collaboration and robust technology.
Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage is thinking differently about drug development by using a focused, practical and deliberate approach. We responsibly pursue expedited pathways in our efforts to deliver new treatments for CNS disorders. At Sage, our mission is to make life better for patients with CNS diseases by discovering, developing, and delivering important new medicines for patients in need.
Samsung Bioepis Co., Ltd.
Samsung Bioepis is a biopharmaceutical company dedicated to unlocking the potential of biosimilar medicines and transforming the way biologic therapies are brought to patients. Our mission is reflected in our name, bio-epis; literally meaning life (“bio”) and science (“episteme”) in Greek. We want to enhance the lives of patients through our pioneering and innovative use of science and technology.
Sandoz
Sandoz is a world leader in generic pharmaceuticals, finding innovative ways to making medicines affordable and accessible to more than 90 percent of the world’s population.Sandoz prides itself on thinking differently. While developing and manufacturing high-quality affordable medicines is core to who we are and what we do, our mission is even greater: We endeavor to make these medicines available to everyone, everywhere. Our portfolio of approximately 1 100 molecules is already available to more than 90% of the world’s population and we continue to work hard to further increase global access.
Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing.
Scipher Medicine
Scipher Medicine holds the fundamental belief that patients deserve simple answers to their treatment options using scientifically backed data. With artificial intelligence and its proprietary molecular technology platform, Scipher Medicine develops innovative diagnostic tests that predict which drug will work from day one and use the data from these tests to develop more effective therapies to improve patient outcomes.
SCYNEXIS, Inc.
We are committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. We believe that our lead compound, Ibrexafungerp (formerly SCY-078), has the potential to be an essential therapy in the treatment of multiple serious fungal infections, including vulvovaginal candidiasis, invasive candidiasis, invasive aspergillosis and refractory invasive fungal infections.
SeaGen
Seagen Inc.is a global biotechnology company that discovers, develops and commercializes transformativecancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on our marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal onTwitter.
Servier
Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2020, Servier employs 22,500 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient’s voice at the heart of its activities, from research to support beyond the pill. A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies.
Sobi
Sobi is an international rare disease company dedicated to providing access to innovative treatments that make a significant difference for people with rare diseases. Strong and growing portfolio: We have two busienss areas: Haemophilia and Specialty Care. Our research and product portfolio is primarily focused on hemophilia, inflammation, and genetic and metabolic diseases. In Hemophilia, we aim to take a leadership position. Sobi is an integraterd biotechnology company with in-house capabilities that encompass the entire value chain, from research to preclinical and clinical development, biologis manufacturing and supply, to patient access and distribution. This integrated approach is a prerequisite for providing proprietary drugs, and an enabler for partnerships, especially at early stages of drug development.
Spero Therapeutics
Spero Therapeutics is a global, multi-asset, clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. Our mission as a leader in the field of Gram-negative antibiotics is to combat MDR infections by developing highly differentiated and transformative antibiotics through cutting edge science that address critical unmet needs.Spero Therapeutics is highly committed to advancing novel treatment approaches for bacterial infections. Our world-class team of biotechnology and biopharmaceutical experts embrace the Italian word “spero” which means “hope.” It is our ultimate goal to bring hope to patients and families of loved ones suffering from serious infections.
SpringWorks Therapeutics
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing medicines for patients living with severe rare diseases and cancer. SpringWorks has a diversified targeted oncology pipeline across solid tumors and hematological cancers, including two late-stage clinical trials in rare tumor types as well as several programs addressing highly prevalent, genetically defined cancers.
Sunovion Pharmaceuticals, Inc.
At Sunovion, patients are at the center of everything we do. We are creating innovative psychiatric, neurological and respiratory therapies that help transform people's lives, while at the same time we are playing an increasingly active role in the future of global health. Our Mission is to broadly contribute to society through value creation based on innovative research and development activities for the betterment of health care and fuller lives of people worldwide. Our Vision is to lead the way to a healthier world and Our Values are to serve and create value for patients; act with the highest standards; trust and empower our people; align, collaborate and win as one team.
Supernus Pharmaceuticals Inc.
With more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) disorders. We are developing several product candidates in neurology and psychiatry to address unmet medical needs and opportunities in epilepsy, attention-deficit hyperactivity disorder (ADHD) and its coexisting disorders, and depression. We are developing differentiated products by leveraging our proprietary and in-licensed technologies. We use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. Our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.
Tabula Rasa HealthCare
Tabula Rasa HealthCare (TRHC) provides new beginnings for our clients, through innovative service models and fresh approaches to healthcare. TRHC provides patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens. We improve patient outcomes, reduce hospitalizations, lower healthcare costs, and manage risk. We deliver our solutions through a comprehensive suite of technology-enabled products and services for medication risk management and risk adjustment.
Taiho Oncology, Inc.
Taiho Oncology, Inc. a division of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd., has built a world class clinical development organization that works urgently to develop innovative cancer treatments and is in the process of building commercial businesses in the USA and Europe. Taiho’s oral oncology pipeline consists of both novel antimetabolic agents and selectively targeted agents.
Takeda Pharmaceuticals America, Inc.
Based in Deerfield, IL, Takeda Pharmaceuticals, U.S.A., Inc and Takeda Development Center Americas, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, respiratory and immunology, gastroenterology, central nervous system and obesity treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for metabolic and cardiovascular disease, central nervous system, oncology and other conditions.
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. The company is studying two investigational medicines in clinical trials. Its lead product candidate, TP-03, is a novel therapeutic being studied in a second Phase 3 pivotal trial for the treatment of Demodex blepharitis. TP-03 is also being developed for the treatment of Meibomian Gland Disease. Tarsus is developing TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease, which is currently being studied in a Phase 1 clinical trial.
Teva Pharmaceuticals
Teva Pharmaceuticals has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and innovative medicines with a portfolio consisting of over 3,600 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of innovative and biopharmaceutical products.
©2023 Teva Neuroscience, Inc. NPS-40577 March 2023
TOLMAR Inc.
TOLMAR is a fully integrated company focused on the development, approval, and commercialization of specialty pharmaceutical products, including a line of generic dermatology products where TOLMAR is an established leader, and specialty injectable oncology products. Invention, development, and worldwide approval of ELIGARD® (leuprolide acetate for injectable suspension) for the palliative treatment of advanced prostate cancer has established TOLMAR as a leader dedicated to the urology community, providers, and patients. TOLMAR has 24 FDA-approved products.
Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.
UCB
UCB's ambition is to transform the lives of people living with severe diseases. We focus on neurology and immunology disorders - putting patients at the center of our world. We are Inspired by Patients. Driven By Science. UCB is continuously working to advance science and embrace new knowledge. We are leveraging scientific advances and skills in areas such as genetics, biomarkers and human biology. Patients inspire us to bring them value through cutting-edge science, innovative drugs, and practical solutions - so that they and their carers can get on with their lives.
uniQure biopharma BV
Our focus is to advance the future of medicine through gene therapy, leveraging our more than 20 years of gene therapy leadership. uniQure is delivering on the promise of gene therapy -- single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and other severe genetic diseases.
Urovant Sciences
Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for a range of urologic conditions. Our goal is to be the leading specialty company, recognized and trusted by patients and providers for our commitment to urology. Our current area of research focus is Overactive Bladder (OAB). We are currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as third line treatments for OAB symptoms in patients who have failed oral pharmacologic therapy.
Valuate Health
We optimize value strategy and commercialization in the healthcare industry. Our consulting practice combines deep market access and reimbursement expertise with industry-leading analytics to demonstrate product value to healthcare stakeholders. We help manufacturers evaluate reimbursement potential for new assets, design and translate HEOR studies, develop and validate product value platforms, respond to health policy changes, understand and support organizational customers, and formulate strategies to ensure products can break through market access barriers to get to patients. Because we believe people deserve access to the healthcare they need.
VBI Vaccines Inc
VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM).
Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. We believe there’s a better way to safely and effectively bring relief to patients, deliver peace of mind to parents and caregivers, and advance accessible therapies to prescribers and payers. We are focused on changing the narrative around skin diseases and making treatment a more efficient process for both physicians and patients.
Viatris
Viatris is a global healthcare company formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer. By integrating the strengths of these two companies, including our global workforce of ~45,000, we aim to deliver increased access to affordable, quality medicines for patients worldwide, regardless of geography or circumstance. Our global portfolio includes best-in-class, iconic brand-name products as well as global key brands; generics, including branded and complex generics; biosimilars; and over-the-counter offerings across a wide range of therapeutic areas. We are committed to helping create healthier communities worldwide through education, outreach and better access to treatment.
Xcenda
For more than 25 years, life science and biotech companies have turned to Xcenda’s leading team of value experts, transforming evidence, policy insights, and market intelligence into effective global market access strategies.
Founded in the application of health outcomes and reimbursement, Xcenda, a part of AmerisourceBergen, is a premier consultancy helping clients effectively navigate today’s complex healthcare landscape. Our bench of diverse experts shares a passion to help you deliver the most distinctive body of evidence that demonstrates your value story.
We strategically execute on actionable insights and differentiating data. We create innovative communications, models and tools so stakeholders understand not only what you’ve created, but why.
It’s our goal to help prove the inherent worth of your products and services, maximize patient access, and enhance your overall brand performance. Trust in our committed team so you can focus on what matters most—helping patients gain access to your brand. Learn more at Xcenda.com.